Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis

NCT05283135 is registered in ClinicalTrials.gov with Oregon Medical Research Center as lead sponsor.

NCT NCT05283135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Lead sponsor
Oregon Medical Research Center
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2022
Completion date
July 10, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis